<DOC>
	<DOCNO>NCT01945606</DOCNO>
	<brief_summary>This study investigate safety tolerability partial A1 agonist BAY1067197 patient chronic heart failure . BAY1067197 apply single dose 30 mg addition standard therapy include beta-blocker . The aim study ass single oral dose 30 mg BAY1067197 well tolerate give top standard therapy heart failure , particularly ß-blocker treatment .</brief_summary>
	<brief_title>Study Assess Safety BAY1067197 Stable Heart Failure Patients Standard Therapy Including ß-blocker</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Stable systolic heart failure ( heart failure reduce ejection fraction , heart failure reduce ejection fraction [ HFrEF ] ; New York Heart Association [ NYHA ] IIII ) sinus rhythm document ejection fraction ( EF ) ≤45 % within last 3 month Stable standard heart failure ( HF ) therapy include intermediate high dose βblocker either ≥ 95 mg metoprolol succinate ( controlled release tablet ) , ≥ 5mg Bisoprolol ( immediate release [ IR ] tablet ) ≥5mg Nebivolol ( IR tablet ) least 4 week . Additional intake angiotensinconverting enzyme ( ACE ) inhibitor angiotensin receptor blocker optional aldosteronereceptor antagonist , diuretic digitalis allow Men confirm postmenopausal woman ( define amenorrheic longer 2 year appropriate clinical profile , e.g . age appropriate history vasomotor symptom ) woman without childbearing potential base surgical treatment bilateral tubal ligation , bilateral ovarectomy , hysterectomy ( documented medical report verification ) . Men enrol study must agree use adequate barrier birth control measure treatment period study 12 week receive investigational medicinal product ( IMP ) Male patient must agree act sperm donor 12 week dose Ethnicity : White Body mass index ( BMI ) : above/equal 18.0 below/equal 29.9 kg/m² Age : 18 75 year ( inclusive ) first screen visit Biventricular pacing/active cardiac resynchronization therapy ( CRT ) device Dependency pacemaker implantable cardioverterdefibrillator ( ICD ) device pacemaker dependency ( paced ventricular rhythm &gt; 5 % heart activity ) A history relevant diseases vital organ heart , central nervous system organ Known hypersensitivity study preparation ( active substance excipients preparation ) βblocker Current history AVBlock &gt; I° Unstable condition , indicate requirement IV drug ( diuretic , inotrope , etc . ) NYHA IV Acute Coronary Syndrome ( define unstable angina [ UA ] , nonST elevation myocardial infarction [ NSTEMI ] , ST elevation myocardial infarction [ STEMI ] ) within 3 month prior first study drug administration History asthma chronic obstructive pulmonary disease ( COPD ) ≥ global initiative chronic obstructive lung disease ( GOLD ) II and/or allergic asthma Women childbearing potential , pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>